CALGARY, ALBERTA--(CCNMatthews - April 25, 2006) - As preparation for entering into the clinical stage of its lead NexVasTM ApoA-I technology program Resverlogix Corp. (“Resverlogix”) (TSX:RVX) announced today that Dr. Gregory S. Wagner has joined the company as Vice President of Preclinical Development. Dr. Wagner will help lead the company’s efforts in developing its cardiovascular programs NexVasTM and ReVasTM towards IND (Investigational New Drug) submission to FDA (Food and Drug administration).
